Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma

MLA

Thomas E Pennington, et al. “Clinicopathological Characteristics of New Primary Melanomas in Patients Receiving Immune Checkpoint Inhibitor Therapy for Metastatic Melanoma.” Australasian Journal of Dermatology, vol. 63, Feb. 2022. EBSCOhost, https://doi.org/10.1111/ajd.13807.

APA

Thomas E Pennington, Cathy Yunjia Zhao, Andrew J Colebatch, Pablo Fernandez‐Peñas, Pascale Guitera, Hazel Burke, Richard A Scolyer, Alexander M Menzies, Matteo S Carlino, Serigne Lo, Georgina V Long, & Robyn PM Saw. (2022). Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma. Australasian Journal of Dermatology, 63. https://doi.org/10.1111/ajd.13807

Chicago

Thomas E Pennington, Cathy Yunjia Zhao, Andrew J Colebatch, Pablo Fernandez‐Peñas, Pascale Guitera, Hazel Burke, Richard A Scolyer, et al. 2022. “Clinicopathological Characteristics of New Primary Melanomas in Patients Receiving Immune Checkpoint Inhibitor Therapy for Metastatic Melanoma.” Australasian Journal of Dermatology 63 (February). doi:10.1111/ajd.13807.